Logo image of MRUS

MERUS NV (MRUS) Stock Price, Quote, News and Overview

NASDAQ:MRUS - Nasdaq - NL0011606264 - Common Stock - Currency: USD

47.37  -0.26 (-0.55%)

After market: 47.37 0 (0%)

MRUS Quote, Performance and Key Statistics

MERUS NV

NASDAQ:MRUS (2/21/2025, 8:00:01 PM)

After market: 47.37 0 (0%)

47.37

-0.26 (-0.55%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High61.61
52 Week Low37.77
Market Cap3.24B
Shares68.46M
Float66.39M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-04 2025-03-04/amc
IPO05-19 2016-05-19


MRUS short term performance overview.The bars show the price performance of MRUS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 15

MRUS long term performance overview.The bars show the price performance of MRUS in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of MRUS is 47.37 USD. In the past month the price increased by 15.23%. In the past year, price decreased by -0.17%.

MERUS NV / MRUS Daily stock chart

MRUS Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About MRUS

Company Profile

MRUS logo image Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 172 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.

Company Info

MERUS NV

Uppsalalaan 17, 3rd & 4th floor

Utrecht UTRECHT 3584 NL

CEO: Sven A. Lundberg

Employees: 201

Company Website: https://merus.nl/

Investor Relations: https://ir.merus.nl/

Phone: 31850162500

MERUS NV / MRUS FAQ

What is the stock price of MERUS NV today?

The current stock price of MRUS is 47.37 USD. The price decreased by -0.55% in the last trading session.


What is the ticker symbol for MERUS NV stock?

The exchange symbol of MERUS NV is MRUS and it is listed on the Nasdaq exchange.


On which exchange is MRUS stock listed?

MRUS stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for MERUS NV stock?

23 analysts have analysed MRUS and the average price target is 88.8 USD. This implies a price increase of 87.46% is expected in the next year compared to the current price of 47.37. Check the MERUS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is MERUS NV worth?

MERUS NV (MRUS) has a market capitalization of 3.24B USD. This makes MRUS a Mid Cap stock.


How many employees does MERUS NV have?

MERUS NV (MRUS) currently has 201 employees.


What are the support and resistance levels for MERUS NV (MRUS) stock?

MERUS NV (MRUS) has a support level at 42.51 and a resistance level at 47.38. Check the full technical report for a detailed analysis of MRUS support and resistance levels.


Is MERUS NV (MRUS) expected to grow?

The Revenue of MERUS NV (MRUS) is expected to decline by -21.2% in the next year. Check the estimates tab for more information on the MRUS EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy MERUS NV (MRUS) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MERUS NV (MRUS) stock pay dividends?

MRUS does not pay a dividend.


When does MERUS NV (MRUS) report earnings?

MERUS NV (MRUS) will report earnings on 2025-03-04, after the market close.


What is the Price/Earnings (PE) ratio of MERUS NV (MRUS)?

MERUS NV (MRUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.9).


What is the Short Interest ratio of MERUS NV (MRUS) stock?

The outstanding short interest for MERUS NV (MRUS) is 11.56% of its float. Check the ownership tab for more information on the MRUS short interest.


MRUS Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to MRUS. When comparing the yearly performance of all stocks, MRUS turns out to be only a medium performer in the overall market: it outperformed 53.23% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MRUS Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MRUS. MRUS has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MRUS Financial Highlights

Over the last trailing twelve months MRUS reported a non-GAAP Earnings per Share(EPS) of -3.9. The EPS decreased by -3.72% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.95%
ROE -34.77%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-239.53%
Sales Q2Q%6.7%
EPS 1Y (TTM)-3.72%
Revenue 1Y (TTM)-21.34%

MRUS Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to MRUS. The Buy consensus is the average rating of analysts ratings from 23 analysts.

For the next year, analysts expect an EPS growth of -27.78% and a revenue growth -21.2% for MRUS


Ownership
Inst Owners105.59%
Ins Owners0.57%
Short Float %11.56%
Short Ratio13.07
Analysts
Analysts87.83
Price Target88.8 (87.46%)
EPS Next Y-27.78%
Revenue Next Year-21.2%